Therapeutic time window of anti-high mobility group box-1 antibody administration in mouse model of spinal cord injury

Masahide Nakajo, Naohiro Uezono, Hideyuki Nakashima, Hidenori Wake, Setsuro Komiya, Masahiro Nishibori, Kinichi Nakashima

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Spinal cord injury (SCI) is a devastating neurologic disorder that often leads to permanent disability, and there is no effective treatment for it. High mobility group box-1 (HMGB1) is a damage-associated molecular protein that triggers sterile inflammation upon injuries. We have previously shown that two administrations of neutralizing monoclonal antibody (mAb) against HMGB1 (immediately after (0 h) and 6 h after) SCI dramatically improves functional recovery after SCI in mice. However, when considering clinical application, 0 h after SCI is not practical. Therefore, in this study, we examined the therapeutic time window of the mAb administration. Injection at 3 h after SCI significantly improved the functional recovery comparably to injection immediately after SCI, while injection at 6 h was less effective, and injection at 9 or 12 h had no therapeutic effect. We also found beneficial effects of injection at 3 h after injury on blood-spinal cord barrier maintenance, inflammatory-related gene expression and preservation of the damaged spinal cord tissue. Taken together, our results suggest that a single administration of anti-HMGB1 mAb within a proper time window could be a novel and potential therapeutic strategy for SCI.

元の言語英語
ページ(範囲)63-70
ページ数8
ジャーナルNeuroscience Research
141
DOI
出版物ステータス出版済み - 4 2019

Fingerprint

Spinal Cord Injuries
Antibodies
Injections
Monoclonal Antibodies
Therapeutics
Spinal Cord
Wounds and Injuries
Therapeutic Uses
Neutralizing Antibodies
Nervous System Diseases
Maintenance
Inflammation
Gene Expression
Proteins

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

これを引用

Therapeutic time window of anti-high mobility group box-1 antibody administration in mouse model of spinal cord injury. / Nakajo, Masahide; Uezono, Naohiro; Nakashima, Hideyuki; Wake, Hidenori; Komiya, Setsuro; Nishibori, Masahiro; Nakashima, Kinichi.

:: Neuroscience Research, 巻 141, 04.2019, p. 63-70.

研究成果: ジャーナルへの寄稿記事

Nakajo, Masahide ; Uezono, Naohiro ; Nakashima, Hideyuki ; Wake, Hidenori ; Komiya, Setsuro ; Nishibori, Masahiro ; Nakashima, Kinichi. / Therapeutic time window of anti-high mobility group box-1 antibody administration in mouse model of spinal cord injury. :: Neuroscience Research. 2019 ; 巻 141. pp. 63-70.
@article{c37a0c8ee25d49b8a45110c331e64b34,
title = "Therapeutic time window of anti-high mobility group box-1 antibody administration in mouse model of spinal cord injury",
abstract = "Spinal cord injury (SCI) is a devastating neurologic disorder that often leads to permanent disability, and there is no effective treatment for it. High mobility group box-1 (HMGB1) is a damage-associated molecular protein that triggers sterile inflammation upon injuries. We have previously shown that two administrations of neutralizing monoclonal antibody (mAb) against HMGB1 (immediately after (0 h) and 6 h after) SCI dramatically improves functional recovery after SCI in mice. However, when considering clinical application, 0 h after SCI is not practical. Therefore, in this study, we examined the therapeutic time window of the mAb administration. Injection at 3 h after SCI significantly improved the functional recovery comparably to injection immediately after SCI, while injection at 6 h was less effective, and injection at 9 or 12 h had no therapeutic effect. We also found beneficial effects of injection at 3 h after injury on blood-spinal cord barrier maintenance, inflammatory-related gene expression and preservation of the damaged spinal cord tissue. Taken together, our results suggest that a single administration of anti-HMGB1 mAb within a proper time window could be a novel and potential therapeutic strategy for SCI.",
author = "Masahide Nakajo and Naohiro Uezono and Hideyuki Nakashima and Hidenori Wake and Setsuro Komiya and Masahiro Nishibori and Kinichi Nakashima",
year = "2019",
month = "4",
doi = "10.1016/j.neures.2018.03.004",
language = "English",
volume = "141",
pages = "63--70",
journal = "Neuroscience Research",
issn = "0168-0102",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Therapeutic time window of anti-high mobility group box-1 antibody administration in mouse model of spinal cord injury

AU - Nakajo, Masahide

AU - Uezono, Naohiro

AU - Nakashima, Hideyuki

AU - Wake, Hidenori

AU - Komiya, Setsuro

AU - Nishibori, Masahiro

AU - Nakashima, Kinichi

PY - 2019/4

Y1 - 2019/4

N2 - Spinal cord injury (SCI) is a devastating neurologic disorder that often leads to permanent disability, and there is no effective treatment for it. High mobility group box-1 (HMGB1) is a damage-associated molecular protein that triggers sterile inflammation upon injuries. We have previously shown that two administrations of neutralizing monoclonal antibody (mAb) against HMGB1 (immediately after (0 h) and 6 h after) SCI dramatically improves functional recovery after SCI in mice. However, when considering clinical application, 0 h after SCI is not practical. Therefore, in this study, we examined the therapeutic time window of the mAb administration. Injection at 3 h after SCI significantly improved the functional recovery comparably to injection immediately after SCI, while injection at 6 h was less effective, and injection at 9 or 12 h had no therapeutic effect. We also found beneficial effects of injection at 3 h after injury on blood-spinal cord barrier maintenance, inflammatory-related gene expression and preservation of the damaged spinal cord tissue. Taken together, our results suggest that a single administration of anti-HMGB1 mAb within a proper time window could be a novel and potential therapeutic strategy for SCI.

AB - Spinal cord injury (SCI) is a devastating neurologic disorder that often leads to permanent disability, and there is no effective treatment for it. High mobility group box-1 (HMGB1) is a damage-associated molecular protein that triggers sterile inflammation upon injuries. We have previously shown that two administrations of neutralizing monoclonal antibody (mAb) against HMGB1 (immediately after (0 h) and 6 h after) SCI dramatically improves functional recovery after SCI in mice. However, when considering clinical application, 0 h after SCI is not practical. Therefore, in this study, we examined the therapeutic time window of the mAb administration. Injection at 3 h after SCI significantly improved the functional recovery comparably to injection immediately after SCI, while injection at 6 h was less effective, and injection at 9 or 12 h had no therapeutic effect. We also found beneficial effects of injection at 3 h after injury on blood-spinal cord barrier maintenance, inflammatory-related gene expression and preservation of the damaged spinal cord tissue. Taken together, our results suggest that a single administration of anti-HMGB1 mAb within a proper time window could be a novel and potential therapeutic strategy for SCI.

UR - http://www.scopus.com/inward/record.url?scp=85045016049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045016049&partnerID=8YFLogxK

U2 - 10.1016/j.neures.2018.03.004

DO - 10.1016/j.neures.2018.03.004

M3 - Article

C2 - 29604317

AN - SCOPUS:85045016049

VL - 141

SP - 63

EP - 70

JO - Neuroscience Research

JF - Neuroscience Research

SN - 0168-0102

ER -